Effect of blood thinning medicine in COVID-19 infectio
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2020/08/027503
- Lead Sponsor
- Dr Souvik Maitra
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Adult (aged between 18 and 65y) patients with laboratory confirmed SARS- CoV-2 infection with hypoxemia (defined by room air SpO2 <= 94%) at the time of randomization will be included.
1.Refusal to participate
2.Mechanically ventilated patients
3.Patients with P/F ratio < 150 mm Hg
4.Patients with any known coagulation disorder
5.Patients with known platelet function disorder
6.Patients who are already on antiplatelet therapy
7.Patients with thrombocytopenia (platelet count < 100,000/ cmm)
8.Patients with any previous intracranial pathology
9.Patients with known gastric/ duodenal ulcer
10.Patients with history of gastro-intestinal bleeding within 3 months
11.Pregnancy women or women who are breastfeeding their children
12.Known allergy to aspirin
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method